-
Trajectories of social isolation and loneliness and the risk of incident type 2 diabetes mellitus across genetic risk score Diabetes Metab. (IF 7.2) Pub Date : 2024-03-06 Yilin Chen, Huachen Xue, Sizhi Ai, Yaping Liu, Yu Nie, Qi-Yong H. Ai, Jihui Zhang, Yannis Yan Liang
Hazard ratios adjusted for age, sex, ethnicity, assessment centers, current employment status, education, Townsend deprivation index, smoking status, alcohol consumption frequency, physical activity, TV watching time, healthy diet score, ever seeking help from physicians due to anxiety or depressive symptoms, antihypertensive medications use, and cholesterol medications use. CI, confidence interval;
-
Association of Ketone Bodies with Incident CKD and Death: A UK Biobank Study Diabetes Metab. (IF 7.2) Pub Date : 2024-03-04 Chan-Young Jung, Hee Byung Koh, Ga Young Heo, Byounghwi Ko, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han
Although cellular and animal models have suggested a protective effect of ketone bodies (KBs), clinical data are still lacking to support these findings. This study aimed to investigate the association of KB levels with incident chronic kidney disease (CKD) and death. This was a prospective cohort study of 87,899 UK Biobank participants without baseline CKD who had plasma levels of β-hydroxybutyrate
-
BedBiopsy: Diagnostic performance of bedside ultrasound-guided bone biopsies for the management of diabetic foot infection Diabetes Metab. (IF 7.2) Pub Date : 2024-03-03 Nolan Hassold, Hélène Bihan, Yolène Pambo Moumba, Isabelle Poilane, Frédéric Méchaï, Nabil Assad, Véronique Labbe-Gentils, Meriem Sal, Omar Nouhou Koutcha, Antoine Martin, Dana Radu, Emmanuel Martinod, Hugues Cordel, Nicolas Vignier, Sopio Tatulashvili, Narimane Berkane, Etienne Carbonnelle, Olivier Bouchaud, Emmanuel Cosson
We aimed to assess the feasibility and diagnostic performance of ultrasound-guided bone biopsies at the bedside of diabetic patients admitted for suspected foot osteitis not requiring surgery. In this retrospective monocentric study, we compared the performance of ultrasound-guided ( = 29 consecutive patients, Dec.2020-Oct.2022) versus surgical ( = 24 consecutive patients, Jan.2018-Nov.2020) bone biopsies
-
-
-
Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: A longitudinal observational study Diabetes Metab. (IF 7.2) Pub Date : 2024-02-11 Fadi Alkhami, Gauthier Borderie, Ninon Foussard, Alice Larroumet, Laurence Blanco, Marie-Amélie Barbet-Massin, Amandine Ferriere, Claire Ducos, Kamel Mohammedi, Sami Fawaz, Thierry Couffinhal, Vincent Rigalleau
Cardiovascular disease is frequent in type 2 diabetes mellitus (T2DM). We investigated the relationship between skin autofluorescence (SAF) of advanced glycation end-products and later cardiovascular events (CVEs) in patients with T2DM. We conducted a retrospective analysis of 504 patients hospitalized for uncontrolled and/or complicated T2DM between 2009 and 2017. SAF was measured using an AGE-Reader
-
Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study Diabetes Metab. (IF 7.2) Pub Date : 2024-02-08 Yu-Chi Su, Pei-Chun Hsieh, Edward Chia-Cheng Lai, Yu-Ching Lin
Theoretically, sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce the risk of rotator cuff tear through an anti-inflammatory mechanism. To clarify this association, in this study, we compared SGLT2i users and glucagon-like peptide-1 receptor agonist (GLP-1 RA) users in terms of the risk of rotator cuff tear and the risk of receiving rotator cuff repair surgery. A retrospective cohort analysis
-
Association between blood urea nitrogen-to-creatinine ratio and insulin sensitivity Diabetes Metab. (IF 7.2) Pub Date : 2024-02-08 JaeHyuck Lee, In Cheol Hwang, Hong Yup Ahn
-
High serum total bilirubin as a potential protective factor for gestational diabetes mellitus: A retrospective cohort study of 92,885 Chinese pregnant women Diabetes Metab. (IF 7.2) Pub Date : 2024-02-08 Yan Zhao, Wenyu Zhu, Miao Wang, Luyi Cai, Xueying Zheng, Liping Jin
Identifying physiological factors that could reduce pregnant women's risk for developing gestational diabetes mellitus (GDM) is crucial for early prevention and intervention. We aimed to examine whether higher serum levels of total bilirubin (TBIL) were associated with a decreased risk of GDM. We conducted a retrospective cohort study in a tertiary care hospital in Shanghai, China. A total of 92,885
-
Glycemic Risk Index (GRI) variability in type 1 diabetes adults with HbA1c ≤ 7%: Insights for clinical evaluation and intervention Diabetes Metab. (IF 7.2) Pub Date : 2024-02-01 Philippe Oriot, Michel P Hermans, Antoine Vandelaer, Jean Christophe Philips, Gaëtan Prévost
Abstract not available
-
Associations of type 2 diabetes and the risk of migraine in Chinese populations Diabetes Metab. (IF 7.2) Pub Date : 2024-01-23 Jielong Wu, Jie Fang, Xiaodong Yuan, Lingshan Ma, Liangcheng Zheng, Qing Lin, Xingkai An, Zhanxiang Wang, Qilin Ma
Aim We aimed to explore the relationship between type 2 diabetes mellitus (T2DM) and the incidence rate of migraine in a Chinese population, and analyze the clinical characteristics of migraine patients with T2DM. Methods Data on the study cohort of 9873 individuals were obtained from the China Health and Retirement Longitudinal Study (CHARLS). The incidence rate of migraine from 2015 to 2018 was assessed
-
Social isolation, loneliness, and the risk of incident type 2 diabetes mellitus by glycemic status Diabetes Metab. (IF 7.2) Pub Date : 2024-01-20 Yanjun Zhang, Mengyi Liu, Chun Zhou, Ziliang Ye, Yuanyuan Zhang, Sisi Yang, Panpan He, Xiaoqin Gan, Xianhui Qin
Aim The modifying effect of prediabetic status on the association of social isolation and loneliness with the risk of type 2 diabetes mellitus (T2DM) remains uncertain. We aimed to explore whether prediabetic status modifies the association of social isolation and loneliness with incident T2DM. Methods 358,951 participants with random blood glucose < 11.1 mmol/l, hemoglobin A1c < 6.5 % and without
-
Hope, hype and present limitations of hybrid closed loop systems for persons with type 1 diabetes Diabetes Metab. (IF 7.2) Pub Date : 2024-01-15 Charles Thivolet
Abstract not available
-
Eleven-year trends in socioeconomic inequalities in the prevalence and incidence of pharmacologically treated type 2 diabetes in France, 2010–2020 Diabetes Metab. (IF 7.2) Pub Date : 2024-01-10 Marie Guion, Laurence Mandereau-Bruno, Sarah Goria, Emmanuel Cosson, Sandrine Fosse-Edorh
Aim This study aimed to describe the association between socioeconomic inequalities and the prevalence and incidence of pharmacologically-treated type 2 diabetes in European France over the 2010–2020 period. Methods Diabetes cases were identified using a validated algorithm from the French National Health Data System. Analysis was restricted to adults aged 45 years and older to focus on type 2 diabetes
-
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review Diabetes Metab. (IF 7.2) Pub Date : 2023-12-28 André J. Scheen
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is), while developed as antihyperglycaemic medications for the treatment of type 2 diabetes, have proven to reduce major cardiovascular adverse events (MACEs) and hospitalization for heart failure (especially for SGLT2is) in dedicated cardiovascular outcome trials. The contribution of
-
Steatotic liver disease, MASLD and risk of chronic kidney disease Diabetes Metab. (IF 7.2) Pub Date : 2023-12-21 Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
With the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the association of this common liver disease with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term non-alcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi
-
Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: Lessons for precision medicine Diabetes Metab. (IF 7.2) Pub Date : 2023-12-21 Youssef Kouidrat, Lauriane Le Collen, Martine Vaxillaire, Aurélie Dechaume, Bénédicte Toussaint, Emmanuel Vaillant, Souhila Amanzougarene, Mehdi Derhourhi, Brigitte Delemer, Mustapha Azahaf, Philippe Froguel, Amélie Bonnefond
Objective Heterozygous pathogenic or likely pathogenic (P/LP) PDX1 variants cause monogenic diabetes. We comprehensively examined the phenotypes of carriers of P/LP PDX1 variants, and delineated potential treatments that could be efficient in an objective of precision medicine. Methods The study primarily involved a family harboring a novel P/LP PDX1 variant. We then conducted an analysis of documented
-
Metformin treatment is associated with improved survival in diabetic patients hospitalized with acute heart failure: A prospective observational study using the Korean acute heart failure registry data Diabetes Metab. (IF 7.2) Pub Date : 2023-12-12 Kyeong-Hyeon Chun, Jaewon Oh, Chan Joo Lee, Jin Joo Park, Sang Eun Lee, Min-Seok Kim, Hyun-Jai Cho, Jin-Oh Choi, Hae-Young Lee, Kyung-Kuk Hwang, Kye Hun Kim, Byung-Su Yoo, Dong-Ju Choi, Sang Hong Baek, Eun-Seok Jeon, Jae-Joong Kim, Myeong-Chan Cho, Shung Chull Chae, Byung-Hee Oh, Seok-Min Kang
-
Reduction of circulating methylglyoxal levels by a Mediterranean diet is associated with preserved kidney function in patients with type 2 diabetes and coronary heart disease: From the CORDIOPREV randomized controlled trial Diabetes Metab. (IF 7.2) Pub Date : 2023-12-12 Francisco M. Gutierrez-Mariscal, Alicia Podadera-Herreros, Juan F. Alcalá-Diaz, Magdalena P. Cardelo, Antonio P. Arenas-de Larriva, Silvia de la Cruz-Ares, Jose D. Torres-Peña, Raul M. Luque, Pablo Perez-Martinez, Javier Delgado-Lista, Jose Lopez-Miranda, Elena M. Yubero-Serrano
Aim Advanced glycation end products (AGEs) play a role in kidney disease in type 2 diabetes mellitus (T2DM). However, there have been no prior controlled clinical trials examining the effects of specific diets on AGE metabolism and their impact on kidney function. Our aim was to assess whether modulating AGE metabolism resulting in reduced AGEs levels, after consumption of two healthy diets, could
-
Increased risk of incident mental disorders in adults with new-onset type 1 diabetes diagnosed after the age of 19: A nationwide cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-12-14 Seohyun Kim, Gyuri Kim, So Hyun Cho, Rosa Oh, Ji Yoon Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
Aim This population-based study aimed to investigate the risk of mental disorders in adults with new-onset type 1 diabetes mellitus compared to the general population without diabetes. Methods We selected 10,391 adults with new-onset type 1 diabetes and 51,995 adults in the general population without diabetes with a median follow-up of 7.94 years using the National Health Insurance Database in South
-
Monitoring gestational diabetes mellitus patients with myDiabby Healthcare® smartphone application vs classical diary. Results from the non-inferiority TELESUR-GDM study Diabetes Metab. (IF 7.2) Pub Date : 2023-12-06 Poncelet C, Bouamoud L, Michel P, Campinos C
Objective The aim of the TELESUR-GDM study was to demonstrate the non-inferiority of the onset of maternal, fœtal, and neonatal complications for patients with gestational diabetes mellitus (GDM) monitored by myDiabby HealthcareⓇ (app group) compared to patients with a classical glycaemic blood monitoring by diary (control group). Materials and methods TELESUR-GDM was a retrospective, monocentric,
-
Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study Diabetes Metab. (IF 7.2) Pub Date : 2023-12-05 María Durán-Martínez, Sharona Azriel, Viyey Kishore Doulatram-Gamgaram, Óscar Moreno-Pérez, Pedro J. Pinés-Corrales, Cristina Tejera-Pérez, Juan Francisco Merino-Torres, Miguel Brito-Sanfiel, Ana Chico, Amparo Marco, Elena García-Fernández, José Ignacio Martínez-Montoro
Objective To assess real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes mellitus (T1DM). Methods We conducted a multicenter retrospective study in Spain including data from 250 people living with T1DM receiving dapagliflozin as add-on therapy to insulin (80.8 % on-label use). The number of diabetic ketoacidosis (DKA) events was calculated over a 12-month follow-up
-
Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes Diabetes Metab. (IF 7.2) Pub Date : 2023-11-28 Yen-Min Huang, Wan-Ming Chen, An-Tzu Jao, Mingchih Chen, Ben-Chang Shia, Szu-Yuan Wu
Purpose According to the preclinical data, sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2is) may exert anticancer effects. Here, we clarified the cancer-specific mortality (primary outcome) and all-cause mortality (secondary outcome) of SGLT2is and their dose-dependency in patients with cancer undergoing standard curative treatments. Methods We analyzed data from patients with type 2 diabetes
-
A healthful plant-based diet is associated with lower type 2 diabetes risk via improved metabolic state and organ function: A prospective cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-11-28 Alysha S. Thompson, Catharina J. Candussi, Anna Tresserra-Rimbau, Amy Jennings, Nicola P. Bondonno, Claire Hill, Solomon A. Sowah, Aedín Cassidy, Tilman Kühn
Background Plant-based diets are becoming increasingly popular due to favourable environmental footprints and have been associated with lower risk of type 2 diabetes mellitus (T2DM). Here, we investigated the potential mechanisms to explain the lower T2DM risk observed among individuals following plant-based diets. Methods Prospective data from the UK Biobank, a cohort study of participants aged 40
-
Low frequency of albuminuria testing among diabetic patients in France: Real-world data from clinical laboratories Diabetes Metab. (IF 7.2) Pub Date : 2023-11-23 Fabrice Bonnet, Léa Longepierre, Dinh-Phong Nguyen, Imène Sedrati, Alegria Marcilla
Abstract not available
-
French National Authority for Health assessment of metabolic surgery for type 2 diabetes remission—A meta-analysis in patients with class I to III obesity Diabetes Metab. (IF 7.2) Pub Date : 2023-11-22 Jean-Charles Lafarge, Judith Aron-Wisnewsky, François Pattou, Michel Cucherat, Emmanuelle Blondet, Sylvie Lascols, , Dominique Le Guludec, Denis-Jean David, Cédric Carbonneil
Objective Randomized controlled trials (RCTs) have demonstrated the superiority of metabolic surgery (MS) over medical therapy (MT) in patients with obesity and type 2 diabetes, leading, to a joint statement in 2016 proposing MS to patients with class I obesity and uncontrolled glycemia. Yet, these RCTs included few patients with class I obesity (body mass index 30–35 kg/m2) and even fewer patients
-
MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus Diabetes Metab. (IF 7.2) Pub Date : 2023-11-20 Alessandro Mantovani, Mario Luca Morieri, Raffaella Aldigeri, Luisa Palmisano, Maria Masulli, Katia Bonomo, Marco Giorgio Baroni, Efisio Cossu, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Roberto Trevisan, Riccardo Maria Pollis, Alessandra Dei Cas, Saula Vigili de Kreutzenberg, Giovanni Targher
Aim We examined whether metabolic dysfunction-associated steatotic liver disease (MASLD) with or without significant fibrosis (assessed by validated non-invasive biomarkers) was associated with an increased risk of prevalent chronic kidney disease (CKD) or diabetic retinopathy in people with type 1 diabetes mellitus (T1DM). Methods We performed a retrospective multicenter cross-sectional study involving
-
Glucometrics knowledge and its relationship to glycemic control in people living with type 1 diabetes: The GluKometrics study: Glucometrics knowledge and glycemic control in type 1 diabetes. Diabetes Metab. (IF 7.2) Pub Date : 2023-11-17 Rebeca Reyes, Oscar Moreno-Perez, Cristina Tejera-Perez, Miguel Brito-Sanfiel, Pedro Pines, Eva Aguilera, Manuel Gargallo, Pedro Rozas-Moreno, Javier Escalada San Martin
Abstract not available
-
Glucagon like peptide-1 receptor agonists in type 1 diabetes Diabetes Metab. (IF 7.2) Pub Date : 2023-10-24 Chao Deng, Wenqi Fan, Xia Li
Abstract not available
-
Key indices of glycaemic variability for application in diabetes clinical practice Diabetes Metab. (IF 7.2) Pub Date : 2023-10-24 Louis Monnier, Fabrice Bonnet, Claude Colette, Eric Renard, David Owens
Near normal glycaemic control in diabetes consists to target daily glucose fluctuations and quarterly HbA1c oscillations in addition to overall glucose exposure. Consequently, the prerequisite is to define simple, and mathematically undisputable key metrics for the short- and long-term variability in glucose homeostasis. As the standard deviations (SD) of either glucose or HbA1c are dependent on their
-
Association between diabetes and stress-induced hyperglycemia with skeletal muscle gene expression of INSR in critically ill patients: A prospective cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-10-18 Priscila Bellaver, Ariell F. Schaeffer, Diego P. Dullius, Daisy Crispim, Cristiane B. Leitão, Tatiana H. Rech
This study aimed to investigate the association between diabetes and stress-induced hyperglycemia with skeletal muscle gene expression of INSR of critically ill patients. Skeletal muscle biopsies were prospectively taken from the vastus muscle, and the expression level of INSR was analyzed using RT-qPCR. Fifty patients were included from April 2018 to September 2018. No significant differences in skeletal
-
Discontinuation of hemodialysis after correction of a major hypothyroidism episode, A case report Diabetes Metab. (IF 7.2) Pub Date : 2023-10-17 Sylvie Daclin, Nelly Ramos, Etienne Larger
Abstract not available
-
Impact of chronic emotions and psychosocial stress on glycemic control in patients with type 1 diabetes. Heterogeneity of glycemic responses, biological mechanisms, and personalized medical treatment Diabetes Metab. (IF 7.2) Pub Date : 2023-10-17 Sylvia Franc, Samir Bensaid, Pauline Schaepelynck, Laurent Orlando, Philippe Lopes, Guillaume Charpentier
Many studies have clearly established that chronic psychosocial stress may sustainably worsen glycemic control in patients with type 1 diabetes mellitus (T1DMM), thus promoting diabetes complications. Chronic psychosocial stress may be due to: i) the long-term accumulation of stressful life events that require readjustment on the part of the individual (loosing friends, changing schools), and/or ii)
-
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus Diabetes Metab. (IF 7.2) Pub Date : 2023-09-12 Alessandro Csermely, Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Roberto Trevisan, Riccardo Maria Pollis, Raffaella Aldigeri, Alessandra Dei Cas, Saula Vigili de Kreutzenberg, Giovanni Targher
Aim We examined whether different insulin administration modalities, i.e., multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII by insulin pumps), are differently associated with the risk of having metabolic dysfunction-associated fatty liver disease (MAFLD), with or without coexisting significant liver fibrosis (assessed by validated non-invasive biomarkers), in adults
-
Hyperglycemia-related anxiety during competition in an elite athlete with type 1 diabetes: A case report Diabetes Metab. (IF 7.2) Pub Date : 2023-09-08 Alexandra Katz, Aidan Shulkin, Meryem K. Talbo, Asmaa Housni, Jane Yardley, Anne-Sophie Brazeau, Rémi Rabasa-Lhoret
Aim Managing blood glucose (BG) levels during intense physical activity is challenging for elite athletes with type 1 diabetes (T1D), as it can lead to unpredictable hyper- or hypoglycemia, which can affect performance. This case study presents an 18-year-old male hockey goalie with hyperglycemia-related anxiety during competition and its impact on his T1D management. Methods Mixed-methods approach
-
Excessive dietary sodium intake augments long-term risk of atrial fibrillation in older adults with hyperglycemia: A community-based prospective cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-09-05 Qin Zhang, Yuqi Guo, Mei Li, Ruizhen Yang, Yanli Yao, Yingxin Zhao, Haipeng Yin, Hua Zhang, Weike Liu, Zhendong Liu
Aim Studies investigating the association between sodium intake and new-onset atrial fibrillation (AF) have come to controversial results. This study aimed to assess the effect of excessive sodium intake on new-onset AF in individuals with hyperglycemia. Methods Between April 2007 and November 2011, 2841 community-dwelling individuals aged 60 years and older were recruited from the Shandong area, China
-
Serum albumin and risk of incident diabetes and diabetic microvascular complications in the UK Biobank cohort Diabetes Metab. (IF 7.2) Pub Date : 2023-09-06 Yang-Wei Cai, Hai-Feng Zhang, Jing-Wei Gao, Zhao-Xi Cai, Jie-Wen Cai, Qing-Yuan Gao, Zhi-Teng Chen, Guang-Hong Liao, Chuan-Rui Zeng, Nuo Chen, Pin-Ming Liu, Jing-Feng Wang, Yang-Xin Chen
Aim To examine the associations between serum albumin and the incidences of diabetes and diabetic microvascular complications in participants of the UK Biobank cohort. Methods There were 398,146 participants without diabetes and 30,952 patients with diabetes from the UK Biobank cohort included in this study. Multivariate-adjusted Cox proportional hazard models were used to analyze the association of
-
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies Diabetes Metab. (IF 7.2) Pub Date : 2023-09-05 André J. Scheen
Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However
-
Cost analysis of continuous glucose monitoring in patients hospitalized in a diabetes department Diabetes Metab. (IF 7.2) Pub Date : 2023-08-31 Valentina Maria PEPE, Sandra WISNIEWSKI, Fatema FALL-MOSTAINE, Luc RAKOTOARISOA, Aurélie BROS, Bénédicte GOURIEUX, Laurence KESSLER
Abstract not available
-
Improved dyspeptic symptoms of type 1 diabetes adults with gastroparesis on hybrid closed loop system: A case series Diabetes Metab. (IF 7.2) Pub Date : 2023-08-30 Franck Phan, Marine Halbron, Sophie Jacqueminet, Marc Popelier, Heithem Soliman, Benoit Coffin, Agnès Hartemann, Chloé Amouyal
Abstract not available
-
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes Diabetes Metab. (IF 7.2) Pub Date : 2023-08-30 Marine Monney, François R Jornayvaz, Karim Gariani
Glucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in response to nutrient ingestion, and plays a role in metabolic homeostasis. GLP-1 receptor agonist has a peripheral and a central action, including stimulation of glucose-dependent insulin secretion and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food intake. Through their
-
Glycemic status during pregnancy according to fasting and post-load glucose values: The association with adverse pregnancy outcomes. An observational study Diabetes Metab. (IF 7.2) Pub Date : 2023-08-28 Emmanuel Cosson, Sopio Tatulashvili, Eric Vicaut, Sara Pinto, Meriem Sal, Charlotte Nachtergaele, Narimane Berkane, Amélie Benbara, Marion Fermaut, Jean-Jacques Portal, Lionel Carbillon, Hélène Bihan
Aim Prognosis of treated hyperglycemia in pregnancy (HIP) may differ according to whether diagnosis following an oral glucose tolerance test (OGTT) is based on high fasting and/or high post-load glucose values. Methods From a multiethnic prospective study, we included 8,339 women screened for HIP after 22 weeks of gestation. We evaluated the risk of large-for-gestational-age (LGA) infant (primary endpoint)
-
Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke Diabetes Metab. (IF 7.2) Pub Date : 2023-08-14 Shen Chen, Hongliang Xue, Rong Huang, Ke Chen, Haoyang Zhang, Xu Chen
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a condition characterized by liver fat accumulation and metabolic abnormalities. Given the potential impact of MAFLD on patient health, it is important to understand its association with major adverse cardiovascular events (MACE) such as myocardial infarction (MI) and stroke. In the prospective UK Biobank cohort, we sought to elucidate
-
Association between maternal autoimmune diseases and offspring risk of type 1 diabetes Diabetes Metab. (IF 7.2) Pub Date : 2023-08-09 Yu-Hsuan Pai, Renin Chang, Cheuk-Kwan Sun, Wen-Bin Yeh
Abstract not available
-
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes Diabetes Metab. (IF 7.2) Pub Date : 2023-08-01 Valeria Grancini, Andrea Gramegna, Laura Zazzeron, Gianfranco Alicandro, Laura L Porcaro, Federica Piedepalumbo, Chiara Lanfranchi, Valeria Daccò, Emanuela Orsi, Francesco Blasi
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to
-
-
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-07-12 Zi-Yang Peng, Yao-Tseng Wang, Chin-Sung Chang, Chih-Hsing Wu, Huang-Tz Ou
Aims To retrospectively analyze the association of sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl peptidase-4 inhibitors (DPP4is) with a range of major and non-major fracture events, and explore heterogeneous treatment effect among high-risk patient subgroups. Methods Newly stable SGLT2i or DPP4i users in 2017 were identified in Taiwan's National Health Insurance Research Database
-
Treatment of women with mild gestational diabetes mellitus decreases the risk of adverse perinatal outcomes Diabetes Metab. (IF 7.2) Pub Date : 2023-06-17 Fanny Goyette, Bi Lan Wo, Marie-Hélène Iglesias, Evelyne Rey, Ariane Godbout
Aims Glycemic thresholds used to diagnose gestational diabetes mellitus (GDM) are a continued subject of debate. Lower glycemic thresholds identify women with milder GDM for whom treatment benefit is unclear. We compared adverse maternal and neonatal outcomes in treated and untreated women with mild hyperglycemia. Methods We reviewed 11 553 patient charts from two tertiary care centers and included
-
Relationship of ultra-processed food consumption and new-onset chronic kidney diseases among participants with or without diabetes Diabetes Metab. (IF 7.2) Pub Date : 2023-06-06 Mengyi Liu, Sisi Yang, Ziliang Ye, Yanjun Zhang, Yuanyuan Zhang, Panpan He, Chun Zhou, Fan Fan Hou, Xianhui Qin
Background Whether diabetes and genetic susceptibility of kidney diseases modifies the relationship between ultra-processed foods (UPF) consumption and incident chronic kidney disease (CKD) remains uncertain. We aimed to investigate the association between UPF consumption and new-onset CKD in participants with and without diabetes, and explore whether genetic risks of kidney diseases may modify the
-
Effect of yoga on reducing glycaemic variability in individuals with type 2 diabetes: A randomised controlled trial Diabetes Metab. (IF 7.2) Pub Date : 2023-06-08 Venugopal Vijayakumar, Ramesh Mavathur, Subramanian Kannan, Manjunath N.K. Sharma, Nagarathna Raguram, Maheshkumar Kuppusamy
Abstract not available
-
A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis Diabetes Metab. (IF 7.2) Pub Date : 2023-06-02 Kathryn J. Potter, Florence Racine, Anne Bonhoure, Valérie Boudreau, Noémie Bélanger, Adèle Coriati, Azadeh Shohoudi, Annick Lavoie, Peter A. Senior, Geneviève Mailhot, Rémi Rabasa-Lhoret
Objectives The classical glycosylated hemoglobin A1c threshold of 6.5% is an insensitive screening test for cystic fibrosis-related diabetes (CFRD). We sought to identify CF-specific A1C thresholds associated with 1) risk of progression to CFRD and 2) changes in body mass index (BMI) and forced expiratory volume (FEV1). Methods We studied the cross sectional and longitudinal associations between A1c
-
Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance Diabetes Metab. (IF 7.2) Pub Date : 2023-05-26 André J. Scheen
Bariatric/metabolic surgery and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are becoming increasingly popular for the management of overweight/obese patients with type 2 diabetes mellitus (T2DM). Consequently, the chance that a patient undergoing bariatric/metabolic surgery is also treated with an SGLT2i would be rather common in clinical practice. Both risks and benefits have been reported
-
Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study Diabetes Metab. (IF 7.2) Pub Date : 2023-05-25 Goh Eun Chung, Kyungdo Han, Kyu-Na Lee, Jung Ho Bae, Sun Young Yang, Su-Yeon Choi, Jeong Yoon Yim, Nam Ju Heo
Objective The effects of nonalcoholic fatty liver disease on the risk of end-stage renal disease (ESRD) remain unclear. We investigated the association between the fatty liver index (FLI) and risk of ESRD in patients with type 2 diabetes. Methods This population‐based observational cohort study enrolled patients with diabetes who underwent health screening between 2009 and 2012 and utilized data from
-
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED) Diabetes Metab. (IF 7.2) Pub Date : 2023-04-26 Atsushi Tanaka, Yosuke Okada, Keiichi Torimoto, Nozomu Kamei, Hiroyuki Hirai, Teruyuki Kono, Kazuhiro Sugimoto, Hiroki Teragawa, Isao Taguchi, Tatsuya Maruhashi, Satomi Sonoda, Akira Kurozumi, Saori Inagaki, Chikage Oshita, Itaru Hisauchi, Kanae Takahashi, Yukihito Higashi, Michio Shimabukuro, Koichi Node
Abstract not available
-
Reply to Dr. Chiang's comments Diabetes Metab. (IF 7.2) Pub Date : 2023-04-06 Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
Abstract not available
-
Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis Diabetes Metab. (IF 7.2) Pub Date : 2023-04-06 Laurence Weiss, Philippe Reix, Helen Mosnier-Pudar, Olivia Ronsin, Jacques Beltrand, Quitterie Reynaud, Laurent Mely, Pierre-Régis Burgel, Nathalie Stremler, Luc Rakotoarisoa, Alfonso Galderisi, Kevin Perge, Nathalie Bendelac, Michel Abely, Laurence Kessler
The increase in life expectancy of patients with cystic fibrosis has come with new comorbidities, particularly diabetes. The gradual development of glucose tolerance abnormalities means that 30 to 40% of adults will be diabetic. Cystic fibrosis–related diabetes is a major challenge in the care of these patients because it is a morbidity and mortality factor at all stages of the disease. Early glucose
-
Pre-gestational diabetes and the risk of congenital heart defects in the offspring: A French nationwide study Diabetes Metab. (IF 7.2) Pub Date : 2023-04-07 Madleen Lemaitre, Gurvan Bourdon, Amélie Bruandet, Xavier Lenne, Damien Subtil, Thameur Rakza, Anne Vambergue
Aim To compare the frequencies and types of congenital heart defects for infants of women without and with pre-gestational diabetes, type 1 and type 2 diabetes (T1DM, T2DM) and to identify risk factors. Methods All live births between 2012 and 2020 were screened for maternal diabetes and infant congenital heart defects using the French Medical Information System Program in Medicine, Surgery and Obstetrics
-
Maternal autoimmune disease associated with a higher risk of offspring with type 1 diabetes: A nationwide mother-child cohort study in Taiwan Diabetes Metab. (IF 7.2) Pub Date : 2023-03-25 Fu-Shun Yen, Jing-Yang Huang, Shih-Yi Lin, Pei-Lun Liao, James Cheng-Chung Wei
Aim The incidence of type 1 diabetes continues to increase. However, the strategies to prevent or reduce its occurrence are inadequate. Therefore, we attempted to investigate if mothers with autoimmune disease were more likely to have children with type 1 diabetes. Methods We identified 1,288,347 newborns from the Taiwan Maternal and Child Health Database between January 1, 2009, and December 31, 2016
-
Association between glycemic status and age-related macular degeneration: a nationwide population-based cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-03-16 Hyungwoo Lee, Kyung-Do Han, Jinyoung Shin
Aim - The risk of dry and wet age-related macular degeneration (AMD) based on fasting glucose levels and disease duration of type 2 diabetes was investigated. Methods - Using a health insurance claims database and the results of health examinations in South Korea, we conducted a retrospective, population-based cohort study of 2,103,604 adults ≥ 45 years of age who were AMD-free based on health checkups
-
Type 2 diabetes and cardiorenal syndromes. A nationwide French hospital cohort study Diabetes Metab. (IF 7.2) Pub Date : 2023-03-15 Valentin Maisons, Jean-Michel Halimi, Grégoire Fauchier, Jean-Baptiste de Fréminville, Nicolas Goin, Juliette Gueguen, Philippe Gatault, Bénédicte Sautenet, Denis Angoulvant, Julien Herbert, Arnaud Bisson, Pierre-Henri Ducluzeau, Laurent Fauchier
Aim . Type 2 diabetes mellitus (T2DM) is a risk factor for cardiac and renal complications; its effect on cardiorenal syndromes is unknown. Methods . In a French nationwide cohort of 5,123,193 patients hospitalized in 2012 with ≥5 years of follow-up, we assessed the effect of T2DM on cardiorenal syndrome (CRS) (using cardiorenal, renocardiac, and simultaneous subtypes) incidence and outcomes using